Rosuvastatin efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Rosuvastatin Efficacy in Lowering LDL Cholesterol and Improving Lipid Profiles
Rosuvastatin is highly effective at lowering low-density lipoprotein (LDL) cholesterol, with reductions ranging from 39% to 63% depending on the dose and patient population. These reductions are greater than those achieved with equivalent doses of other statins such as atorvastatin, simvastatin, and pravastatin, enabling more patients to reach their LDL cholesterol goals Mckenney2005Brown2002. Rosuvastatin also improves other lipid parameters, including triglycerides, non-high-density lipoprotein (HDL) cholesterol, and HDL cholesterol, resulting in a more favorable overall lipid profile Mckenney2005Brown2002Kim2024+1 MORE.
Comparative Efficacy: Rosuvastatin vs. Other Statins
When compared directly to pravastatin and simvastatin, rosuvastatin consistently produces greater reductions in LDL cholesterol and higher rates of LDL goal achievement in patients with hypercholesterolemia . In patients with coronary artery disease, rosuvastatin and atorvastatin show similar efficacy for major cardiovascular outcomes over three years, but rosuvastatin achieves lower average LDL cholesterol levels . In the context of cerebral infarction, both loading-dose atorvastatin and rosuvastatin are effective, but rosuvastatin provides superior blood lipid control .
Efficacy in Special Populations: Children, Adolescents, and East Asians
Rosuvastatin is effective in children and adolescents with familial hypercholesterolemia, reducing LDL cholesterol by up to 50% at the highest allowed dose, though only a minority reach stringent LDL targets due to high baseline levels Avis2010Braamskamp2015. In East Asian populations, both generic and proprietary rosuvastatin formulations demonstrate similar efficacy in lowering LDL cholesterol, with no significant differences in lipid profile changes or adverse events .
Efficacy in Metabolic Syndrome and Fatty Liver Disease
In patients with metabolic syndrome and moderate to severe metabolic associated fatty liver disease (MAFLD), rosuvastatin significantly reduces hepatic fat content and improves lipid metabolism without compromising safety, supporting its use in this population .
Combination Therapy: Rosuvastatin with Ezetimibe
Combining moderate-intensity rosuvastatin with ezetimibe is not only non-inferior but also superior to high-intensity rosuvastatin monotherapy in reducing LDL cholesterol and achieving comprehensive lipid targets in high cardiovascular risk patients with type 2 diabetes mellitus .
Rosuvastatin Safety Profile
Rosuvastatin has a safety profile similar to other statins, with low rates of muscle, liver, and kidney toxicity. Large-scale and long-term studies show a low overall adverse event rate, with no significant increase in statin-associated myopathy, hepatotoxicity, or diabetes in general populations Mckenney2005Kim2024. In children and adolescents, rosuvastatin is well tolerated, with no adverse effects on growth or sexual maturation Avis2010Braamskamp2015. In real-world clinical practice, rosuvastatin remains safe and effective, with a notably low adverse event rate .
Notable Safety Considerations
While most safety outcomes are comparable to other statins, rosuvastatin is associated with a slightly higher risk of new-onset diabetes mellitus requiring antidiabetic medication and cataract surgery compared to atorvastatin in adults with coronary artery disease . Drug interactions can occur with cyclosporine, gemfibrozil, warfarin, and antacids, but overall, the risk of clinically significant adverse events remains low .
Conclusion
Rosuvastatin is a potent and effective statin for lowering LDL cholesterol and improving overall lipid profiles across diverse patient populations, including adults, children, and those with metabolic syndrome or fatty liver disease. Its safety profile is comparable to other statins, with some specific risks to consider in certain populations. Rosuvastatin remains a valuable option for managing dyslipidemia and reducing cardiovascular risk Mckenney2005Brown2002Kim2020+7 MORE.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
Rosuvastatin effectively lowers LDL cholesterol and non-HDL-cholesterol levels, enabling more patients to reach their LDL cholesterol goals with an acceptable safety profile compared to other statins.
DOI